Pharma clinical trial a first for Australia
PERTH: A Perth-based start-up developing a treatment for cystic fibrosis has secured $20 million, to progress a large Australian trial, from a government and industry backed fund described as a “big change” for the industry.
The treatment is among three new Australian medical innovations to be selected for commercial development assistance from the $500m Biomedical Translation Fund.
The fund, made up of equal parts federal government and business funding, is operated by three private sector fund managers. One of the managers, Brandon Capital Partners, has allocated $20m to progress a trial of Respirion Pharmaceuticals’ treatment for cystic fibrosis, which causes increased inflammation and infection in the lungs and ultimately leads to respiratory failure.
Chris Nave, managing director of Brandon Capital Partners, said his fund had stuck to the spirit of the BTF, which he said not all managers had. He added Brandon Capital Partners only put its BTF money into clinical stage Australian assets.
“This investment is another example of doing what the BTF is intended to do,” Mr Nave said.
“It has been recognised that Australia has great medical clinical research and is good at building early stage assets. But they are then often licenced offshore.
“The BTF enables us to put in this investment to develop this asset clinically here in Australia so we aren’t having to pack up the company and take it to the US to raise this money.”
Respirion’s therapy is an inhaled version of the existing antibiotic to treat cystic fibrosis, combined with an agent which boosts the effect of the antibiotic. The cystic fibrosis bacteria exists in protected biofilms, which makes infection very difficult to eradicate. Respirion’s novel formulation helps break down the biofilms, which will improve the efficacy of the antibiotic.
The technology for the treatment was developed by Professor Barry Clements at the Telethon Kids Institute in Perth.
Respirion, which was spun out from the Telethon Kids Institute, has also received a $4.3m grant from the Cystic Fibrosis Foundation, based in the US.
Mr Nave said $20m was one of the most significant commitments Brandon Capital Partner’s BTF fund had made.
“There has been a pilot in-human study that was encouraging. The funds will be used to run a larger study in Australia,” he said.
“Because we are able to put in $20m, it means groups like the Cystic Fibrosis Foundation in the US are willing to come in and put a commitment alongside us because they know we have the capacity to fund this study through to completion,” Mr Nave said.
Health Minister Greg Hunt said the BTF combined government and private support with industry expertise: “These projects will potentially improve the quality of life for millions of people.”
Another of the three fund managers, OneVentures, has allocated $4m from the BTF towards clinical trials and development of a therapeutic device, developed by Madorra, that could relieve the suffering of millions of women.
Madorra’s device treats problems associated with vulval and vaginal atrophy. The initial target group will be women who have survived cancer where hormone replacement therapy is not a viable treatment option.
OneVentures has, to date, also invested $17.2m from the BTF for development of a drug to treat fibrosis, a disease with a high morbidity rate which affects many organs, for which there is no effective treatment. It particularly affects the lungs, kidneys and liver.
Minister for Industry, Science and Technology Karen Andrews said the BTF provided a significant boost to Australian innovation and commercialisation: “The BTF shows Australia has the resources and expertise to assist our world-leading researchers deliver life-changing outcomes for patients through commercialising great Australian ideas.”






